Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Clin Exp Hypertens ; 40(8): 703-714, 2018.
Article in English | MEDLINE | ID: mdl-29351002

ABSTRACT

BACKGROUND: Ginkgo biloba leaves extract has been widely used worldwide to protect against oxidative stress-induced cell damage and improves blood circulation. METHODS: The potential protective role of the standardized leaf extract of Ginkgo biloba (EGb761) on hypertension-induced renal injury was investigated in rats. Hypertension was induced in rats by L-NAME. RESULT: Repeated treatment with EGb761 produced progressive reductions in the systolic, diastolic and mean arterial blood pressure. Also, EGb761 increased the progressive reductions in blood pressure induced by losartan. Hypertension-induced marked elevation of renal malondialdehyde (MDA) and nitrite levels and reduction of reduced glutathione (GSH) level were inhibited by EGb761. In addition, hypertension-induced increases in tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and interleukin-1ß (IL-1ß)) levels in renal tissues were inhibited by EGb761. Also, treatment with EGb761 inhibited hypertension-induced decrease in endothelial nitric oxide synthase (eNOS) protein expression and increase in the protein expressions of inducible NO synthase (iNOS), TNF-α, IL-6 and IL-1B in the kidney tissues. EGb761 enhanced losartan effects on renal tissues oxidative stress, nitrite, and inflammatory markers levels and on protein expressions of eNOS, iNOS, TNF-α, IL-6 and IL-1B. effects. CONCLUSIONS: These results indicate that EGb761 has the ability to protect against hypertension-induced renal injury.


Subject(s)
Arterial Pressure/drug effects , Cardiovascular Agents/therapeutic use , Hypertension/complications , Kidney Diseases/prevention & control , Plant Extracts/therapeutic use , Animals , Antihypertensive Agents/pharmacology , Cardiovascular Agents/pharmacology , Ginkgo biloba , Glutathione/blood , Hypertension/chemically induced , Hypertension, Renal/metabolism , Interleukin-1beta/metabolism , Interleukin-6/metabolism , Kidney/drug effects , Kidney/metabolism , Kidney Diseases/etiology , Kidney Diseases/metabolism , Losartan/pharmacology , Male , Malondialdehyde/blood , NG-Nitroarginine Methyl Ester , Nitric Oxide Synthase Type II/metabolism , Nitric Oxide Synthase Type III/metabolism , Oxidative Stress/drug effects , Plant Extracts/pharmacology , Rats , Tumor Necrosis Factor-alpha/metabolism
2.
Biomed Pharmacother ; 95: 944-955, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28915536

ABSTRACT

The potential protective role of the standardized leaf extract of ginkgo biloba (EGb761) on hypertension with hypercholesterolemia-induced renal injury was investigated in rats. Hypertension was induced by L-N(G)-nitroarginine methyl ester (L-NAME) and hypercholesterolemia was induced by feeding rats with a diet containing 1% cholesterol. In these animals repeated treatment with EGb761 produced a progressive reduction in the systolic, diastolic and mean arterial blood pressure (BP). EGb761 increased the progressive reduction in the systolic, diastolic and mean arterial BP induced by repeated administration of losartan with simvastatin. EGb761 corrected the compromised serum lipid profile and enhanced the effect of losartan with simvastatin on lipid profile. EGb761 protected against hypertension with hypercholesterolemia-induced renal injury as assessed by measurement of serum renal function markers and by histopathological examination. EGb761 enhanced the renoprotective effect of losartan with simvastatin in these rats. Concomitantly, hypertension with hypercholesterolemia-induced elevation of renal tissue malondialdehyde (MDA) and nitrite levels and reduction of intracellular reduced glutathione (GSH) level were inhibited by repeated treatment with EGb761. In addition, hypertension with hypercholesterolemia-induced increases in tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and interleukin-1ß (IL-1ß) levels in renal tissues were inhibited by treatment with EGb761. Also, EGb761 inhibited hypertension with hypercholesterolemia-induced decrease in endothelial nitric oxide synthase (eNOS) protein expression and increase in the protein expressions of inducible NO synthase (iNOS), TNF-α, IL-6 and IL-1ß in the kidney tissues. Losartan with simvastatin produced similar effects on renal tissues oxidative stress, nitrite and inflammatory markers levels and on protein expressions of eNOS, iNOS, TNF-α, IL-6 and IL-1ß. EGb761 enhanced losartan with simvastatin effects. These results indicate that EGb761 has the ability to protect against hypertension with hypercholesterolemia-induced renal injury. The ability of EGb761 to provide this renoprotective effect may positively correlate, besides its antihypertensive and antihypercholesterolemic effects, to its ability to suppress renal oxidative stress, nitrosative stress and inflammation.


Subject(s)
Hypercholesterolemia/complications , Hypercholesterolemia/drug therapy , Hypertension/complications , Hypertension/drug therapy , Kidney/injuries , Plant Extracts/therapeutic use , Protective Agents/therapeutic use , Animals , Blood Pressure/drug effects , Creatinine/blood , Diastole/drug effects , Ginkgo biloba , Glutathione/metabolism , Hypercholesterolemia/physiopathology , Hypertension/physiopathology , Kidney/drug effects , Kidney/pathology , Kidney/physiopathology , Lipids/blood , Losartan/pharmacology , Losartan/therapeutic use , Male , Malondialdehyde/metabolism , Nitric Oxide Synthase Type III/metabolism , Nitrites/metabolism , Plant Extracts/administration & dosage , Plant Extracts/pharmacology , Protective Agents/pharmacology , Rats, Wistar , Simvastatin/pharmacology , Simvastatin/therapeutic use , Systole/drug effects , Urea/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...